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suggest this intriguing approach may be a reality in the near future (24-
26). Finally, all therapy in the setting of metastatic disease is ultimately 
palliative. Consequently treatment decisions should be tempered by this 
sobering reality. 
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Recent years have witnessed improvements in the non-invasive staging 
of NSCLC and image-guided radiotherapy delivery, and it has seen an 
increased use of concurrent chemo-radiotherapy (CT-RT) for locally 
advanced NSCLC. This review will highlight clinical developments in 
3 key areas of NSCLC. 
Stage III NSCLC 
Two randomized trials have shown that the addition of surgery does 
not improve survival in comparison to either sequential CT-RT [1] or 
concurrent CT-RT alone [2]. A meta-analysis concluded that concurrent 
administration of concurrent CT-RT improved survival when compared 
to sequential CT-RT, but at the expense of increased acute esophagitis 
[3]. Despite an increased risk of hospitalizations, concurrent RT-CT is 
not a more costly treatment strategy [4]. Stage III NSCLC consists of a 
number of different subgroups of varying prognosis, and it is reason-
able to expect that further progress will come about in tailoring strate-
gies for subgroups that vary in risk for local recurrence and distant 
metastases. In patients at high risk for toxicity with concurrent CT-RT, 
use of sequential chemotherapy followed by accelerated radiotherapy 
schemes appears to result in favourable outcomes [5-6]. Clinically 
important subgroups include the following: 
i. Extent of nodal disease: Increase in the number of sites of nodal 
disease is associated with decreased survival [7]. For CT-RT in 
NSCLC, at least two major prognostic subgroups can be distin-
guished. The ﬁrst includes patients with small volume and/or single-
station N2 disease (ëoperable diseaseí). Patients included in trials of 
only CT-RT have tended to be characterised by metastases in two or 
more nodal stations and/or bulky nodes exceeding 3 cm. A median 
survival of 22.2 months has been reported for the former [2], while 
the best median survivals reported in randomised trials for the latter 
range from 17 to 17.5 months [8-9]. 
ii. Risk of treatment-related toxicity: The volume of normal lung 
treated to 20 Gy or more (V20) correlates with the risk for high-
grade pulmonary toxicity with CT-RT. A recent study revealed a 
poorer survival in patients with V20 values of ≥35% [10]. Clinical 
presentations that predict for high V20 values include metastases in 
the contralateral hilus and peripheral lower lobe tumors with contra-
lateral upper mediastinal nodes. The risk of high-grade esophagitis 
correlates with the volume of organ irradiated to high doses and the 
number of involved nodal stations [11].
Modern image-guided radiotherapy is now becoming available at major 
centers worldwide but the major clinical trials published in the last 2 
years mainly used 2-dimensional radiotherapy planning and elective 
nodal irradiation. Involved-ﬁeld radiotherapy is now the standard of 
care in stage III NSCLC as it results in both a lower incidence of pneu-
monitis and improves survival [12]. CT-based treatment planning is 
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mandatory for such involved-ﬁeld radiotherapy [13]. Lung toxicity can 
be reduced by minimizing the volume of lung receiving doses in the 
range of 5-15 Gy [14-16]. The development of respiration-correlated 
CT (or 4D) scans permits use of i) patient speciﬁc motion-management 
strategies to reduce the planning margins used to account for tumor 
motion [17-18]. 4DCT also permits use of techniques such as respira-
tion-gated radiotherapy delivery, which permits use of smaller ﬁelds by 
limiting treatment delivery to selected phases of respiration. Although 
higher radiation doses are feasible in selected patients with stage III 
disease, there is no evidence to support the routine use of doses higher 
than 64-66 Gy with concurrent CT-RT. 
Stage I NSCLC 
In medically inoperable stage I NSCLC, local control rates in the range 
of 85-95% have been consistently reported after stereotactic radiother-
apy (SRT) [19]. SRT is typiﬁed by the following features: (1) accurate 
repositioning during treatment simulation and delivery, (2) stereotactic 
registration, using either ﬁducial markers or surrogates of the tumor 
and critical normal organs, to the treatment delivery unit, (3) use of up 
to 10 or more radiation ﬁelds to minimize normal tissue exposure, (5) 
ablative doses delivered with high accuracy, and (6) treatment that is 
typically delivered in 3-5 fractions. Symptomatic radiation pneumonitis 
after SRT occurs in less than 5% of patients [20-21], and the quality 
of life is maintained following SRT, even in patients with considerable 
co-morbidity [21]. 
These results compare favourable with the outcomes of conventional 
radiotherapy, where 3- and 5-year disease-speciﬁc survivals range from 
39±10% and 25±9%, respectively [22]. SRT-related toxicity for periph-
erally located tumors compares very favourably with that after surgery. 
Surgery results in overall 5-year survival of 67% for T1N0M0 tumours, 
and 57% for T2N0M0 tumours [23]. A retrospective review of results 
of SRT at Japanese centers included a number of operable patients in 
whom the 3-year overall survival rates were similar to that reported 
for surgery [24]. Population-based analyses in Europe report post-op 
mortality rates ranging from 1.7% in patients younger than 60 years, to 
9.4% in octogenarians treated for lung cancer [25]. A similar analysis 
from the United States revealed post-operative mortality rates ranging 
from 4.5% for lobectomy, to 8.5% for pneumonectomy [26]. Deteriora-
tion in quality of life is common post-surgery [27] with post-thoracoto-
my pain syndromes observed in more than 50% of patients [28-30]. 
Interest in surgical procedures that preserve lung parenchyma and SRT 
are based on an awareness of the need to preserve pulmonary func-
tion and maintain quality of life. In addition, minimising loss of lung 
function is important due to the incidence of a subsequent primary lung 
cancer at a rate of 1-2% per patient-year [31]. Non-invasive staging for 
SRT can risk failing to detect hilar and mediastinal nodal metastases, 
although this is offset by the fact that a majority of all recurrences fol-
lowing surgery for stage I NSCLC were systemic (20%), as opposed to 
only 7% being local or regional [31]. Prospective randomized clinical 
trials are now being awaited in order to establish the role of SRT in 
patients who are otherwise ﬁt for surgery. 
Post-operative radiotherapy (PORT)
Adjuvant chemotherapy improves survival in patients who have under-
gone radical surgery for stages II and III NSCLC [32]. Despite adjuvant 
chemotherapy, a local tumor recurrence manifests in between 40-60% of 
patients with N2 disease [33-34]. A recent SEER analysis suggested that 
PORT improves the survival in patients with resected N2 disease, and 
this retrospective analysis also conﬁrmed the suggestion of an earlier 
meta-analysis [35] of a poorer survival after PORT in patients with re-
sected N0 and N1 disease [36]. Interest in PORT was also stimulated by 
the ﬁndings of the ANITA trial of adjuvant post-op chemotherapy versus 
observation [37]. The decision to administer postoperative radiotherapy 
in ANITA was not randomised, and a descriptive analysis suggested 
that radiotherapy could beneﬁt patients with N2 disease and be harmful 
when combined with chemotherapy in patients with N1 status.
The median follow-up in the SEER analysis was relatively short and 
longer follow-up is needed to study the late toxicity of PORT. A new 
European phase III trial has been activated to compare modern PORT 
to no PORT in patients with N2 disease (PI. C LePechoux). The 
LungART study includes patients with completely resected N2 disease, 
and use of adjuvant or neo-adjuvant chemotherapy is permitted. Seven 
hundred patients will be included to show a 10% difference in 3-year 
disease-free survival, the primary end-point. Secondary study end-
points are overall survival, patterns of relapse, local failure, second 
cancers, treatment-related toxicity. 
Conclusions 
Advances in image-guided radiotherapy have had a major impact on 
outcomes in early-stage NSCLC. Both improved patient selection and 
image-guided radiotherapy can improve the therapeutic ratio of CT-RT 
in stage III NSCLC. Despite these advances, a large proportion of 
patient will develop recurrent disease. A patient-tailored approach that 
takes into account tumor genomics and prognostic factors that predict 
for treatment toxicity will play an increasingly important role in the 
design of new clinical trials.
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The standard operative procedure for lung cancer is lobectomy and 
mediastinal lymph nodes sampling or dissection. This concept has been 
unchanged for these 3 decades.
But detected lung cancer shifts to earlier stages and preoperative work 
up becomes more accurate than before, with development of diag-
nostic equipments. For instance, about half of resected lung cancer 
population has shifted to stage IA in Japan and population of stage III 
has decreased. This tendency comes from vast spread of high technol-
ogy CAT scan and PET scan. Early detection of lung cancer becomes 
increasing and marginal cases of stage III turned out to be stage IV with 
those developments.
In Japan, ratio of adenocarcinoma reached up to 70% in Non small cell 
lung cancer, and ratio of squamous and small cell carcinoma is decreas-
ing. We have to consider adoption of less invasive surgery for that early 
stage lung cancer. Unfortunately, a randomized trial, which was con-
ducted by Ginsberg and reported on 1995, could not show equivalence 
of limited resection to lobar resection for T1N0 lung cancer. This report 
resulted that limited resection had more frequently relapsed locally. 
Now ACOSOG conducts randomized trial of sublobar resection with 
or without brachytherapy in high risk patients with non-small cell lung 
cancer (Z4032).
From Japan, several retrospective studies about segmentectomy for 
early stage lung cancer has reported to have fair results (81-89% of 5 
year survival), comparing traditional lobectomy, although those studies 
are retrospective studies. We have to conduct a prospective study to 
conﬁrm those data. Japan Clinical Oncology Group is now planning to 
compare segmentectomy vs. lobectomy for clinical stage IA less than 
2 cm diameter, which located outer layer of the lung and has no hilar 
lymph node metastasis conﬁrming by intraoperative lymph node exam-
ination of frozen sections. We are also planning other prospective phase 
II study for wedge resection of peripherally existing non invasive type 
lung cancer, deﬁned as lesion which has more than 3 fourths of ground 
glass opacity at CT scan. Noguch et al. reported that bronchioalvelar 
type of lung cancers deﬁned as Noguch type A and B showed no hilar 
metastasis and no relapse after conventional lobectomy. We hypoth-
esized that the lesion with more than 3 fourths of ground glass opacity 
should be matched as those Noguch A or B. We have performed 
prospective analysis whether CT scan ﬁndings foresight pathological 
early lung cancer (JCOG0204). It failed to show the complete boundary 
by CT scan ﬁndings with pathological non invasiveness. At least, small 
sized lung cancer which has more than 3 fourths of ground glass opac-
ity at CT scan has no hilar and mediastinal lymph node metastasis. This 
studies primary end point is rate of 5 year surviva with local relapse 
and surgical morbidities.
There is another strategy of less invasive surgery deﬁned as video as-
sited thoracoscopic surgery. Advancement of surgical equipments and 
video systems makes VATS lobectomy more safe than before. Although 
the evolution of this technique is still slow. In Korea, several surgeons 
are now conducting feasibility studies about VATS lobectomy, which 
primary end point is morethan 90 % of safely completetion of VATS 
lobectomy.
IALT study, JBR10 and ANITA study demonstrated efﬁcacy of adju-
vant chemotherapy for completely resected non-small cell lung cancer. 
Adjuvant chemotherapy with platinum contained regimen is now 
standard of care for stage II-III. From Japan, we reported the efﬁcacy 
of UFT for completely resected stage Ib non-small cell lung cancer. But 
we still have no information whether pre or post adjuvant chemothera-
py is more effective. We do not know what kind of factors are relating 
to effectiveness of adjuvant chemotherapy. Those issues will become 
clear within several years through many translational studies.
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After approximately 20-30 years of extensive preclinical studies on 
the molecular events important in lung cancer, eventually molecularly 
targeted agents have seen some success in advanced non-small cell 
lung cancer. Two of these have already been registered (erlotinib and 
bevacizumab), and several others are under extensive investigation in 
phase III trials in different settings of the disease. The targets of the 
ﬁrst two agents to see the registration, i.e. EGFR and VEGF, are clearly 
prototypes of targets that are important in several tumors and will have 
broader applicability. Whereas targeting EGFR sensitive patients has 
become easier with the use of mutation anaysis and FISH for EGFR, 
the use of bevacizumab in combination with standard chemotherapy 
at this moment cannot be adequately targeted by a proper patient 
selection. Among novel angiogenesis inhibitors, are very many small 
molecules that target the receptors for VEGF and other molecules 
involved in angiogenesis, such as PDGFRs. Several of these agents 
are being actively tested in phase III studies (e.g. sorafenib, ZD6474) 
or large phase II studies (e.g. sunitinib, ZD2171). It is already evident 
that some of these molecules have single agent activity and although 
tehy have been tested in all NSCLC histologies (including squamous 
carcinomas), they appear to have similar toxicities as reported with 
bevacizumab (cavitation and bleeding). More extensive studies will be 
needed to unravel speciﬁc differences.
At least three “immunologically based” therapeutics are being inves-
tigated in large studies in NSCLC. BL25, a Muc-1 vaccine is being 
tested in stage III unresectable patients in a phase III trial. Recombinant 
Mage-3 has been investigated in the adjuvant setting in a large phase 
II randomized study and in proceeding into phase III. Two phase III 
studies of a Toll-9 agonist have recently been completed in advanced 
NSCLC.
A large number of other molecules are being developed in advanced 
NSCLC. Some of these will clearly have more efﬁcacy in selected 
patients than in the general population, and will likely have the best 
results in less advanced stages of the disease.
